IDBS
- 3 profiles
- 7 categories
All Products & Services
E-WorkBook Inventory is a simple-to-use web solution which enables you to seamlessly manage all your laboratory inventory needs from one place, helping you save time and boost productivity.
IDBS provides the best cloud-based R&D technology and solutions to the world‚ most forward-thinking companies, helping them solve global challenges.
IDBS PIMS is a cloud-native, 21 CFR Part-11 compliant platform that transforms biopharma manufacturing by contextualizing and centralizing critical process and quality data across batches and products. It enables real-time monitoring, deviation investigation, and regulatory reporting, while supporting collaboration across internal teams and external partners. With seamless integration to systems like MES, LIMS, and ERP, PIMS empowers manufacturers to optimize processes, reduce batch failures, and accelerate validation and tech transfer.
IDBS Reviews
carillo r.
E-work book cloud backup very easy and fast
ovidio v.
Cloud depth integration into the software you love
Verified User in Biotechnology
Easily My Favorite ELN
About
What is IDBS?
IDBS helps BioPharma organizations unlock the potential of AI/ML to improve the lives of patients. As a trusted long-term partner to 80% of the top 20 global BioPharma companies1, IDBS delivers powerful cloud software and services specifically designed to meet the evolving needs of the BioPharma sector. IDBS, a Danaher company, leverages 35 years of scientific informatics expertise to help organizations design, execute and orchestrate processes, manage, contextualize and structure data and gain valuable insights throughout the product lifecycle, from R&D through manufacturing. Known for its signature IDBS E-WorkBook software, IDBS has extended its flexible, scalable solutions to the IDBS Polar and PIMS cloud platforms to help scientists make smarter decisions with assured confidence in both GxP and non-GxP environments. Visit idbs.com, to learn more about IDBS. 1. Rank measured by Market Cap, Q1 2024.